Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Summary

This phase II trial studies how well mirvetuximab soravtansine works as first line in treating patients with triple negative breast cancer. Drugs used in chemotherapy, such as mirvetuximab soravtansine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start

2017-06-05

Primary completion

2019-10-01

Completion

2019-10-01

Drugs

Indications